Tags

Type your tag names separated by a space and hit enter

Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Expert Rev Anticancer Ther. 2006 Jan; 6(1):5-10.ER

Abstract

The third-generation aromatase inhibitor letrozole offers a promising approach to treating hormone-sensitive breast cancer for postmenopausal women, through potent and specific inhibition of estrogen synthesis. In neoadjuvant and first-line treatment, letrozole demonstrated superior efficacy compared with tamoxifen in randomized Phase III trials. Initial results of Breast InterGroup 1-98, a large ongoing randomized trial investigating primary adjuvant endocrine treatment with either letrozole or tamoxifen, have recently been presented. Patients treated with letrozole demonstrated a 19% improvement in disease-free survival and a significant reduced risk of distant recurrences, holding out the prospect of a survival advantage over tamoxifen treatment with further maturation of the trial. For patients who have already completed 5 years of tamoxifen, extended endocrine therapy with letrozole is a new therapeutic option based on the results of the MA-17 trial. The optimal use of aromatase inhibitors remains an open question, at least until results from randomized trials (BIG 1-98, TEAM) investigating the sequential use of an aromatase inhibitor and tamoxifen in comparison with continuous monotherapy become available.

Authors+Show Affiliations

Koeberle D
Department of Oncology/Hematology, Kantonsspital St Gallen, CH -9007 St Gallen, Switzerland. dieter.koeberle@kssg.ch
Thuerlimann B
No affiliation info available

MeSH

AgedAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsDisease-Free SurvivalFemaleHumansLetrozoleMiddle AgedNeoadjuvant TherapyNitrilesPostmenopauseRandomized Controlled Trials as TopicTamoxifenTriazoles

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16375638

Citation

Koeberle, Dieter, and Beat Thuerlimann. "Letrozole as Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer." Expert Review of Anticancer Therapy, vol. 6, no. 1, 2006, pp. 5-10.
Koeberle D, Thuerlimann B. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Expert Rev Anticancer Ther. 2006;6(1):5-10.
Koeberle, D., & Thuerlimann, B. (2006). Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Expert Review of Anticancer Therapy, 6(1), 5-10.
Koeberle D, Thuerlimann B. Letrozole as Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer. Expert Rev Anticancer Ther. 2006;6(1):5-10. PubMed PMID: 16375638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. AU - Koeberle,Dieter, AU - Thuerlimann,Beat, PY - 2005/12/27/pubmed PY - 2006/2/16/medline PY - 2005/12/27/entrez SP - 5 EP - 10 JF - Expert review of anticancer therapy JO - Expert Rev Anticancer Ther VL - 6 IS - 1 N2 - The third-generation aromatase inhibitor letrozole offers a promising approach to treating hormone-sensitive breast cancer for postmenopausal women, through potent and specific inhibition of estrogen synthesis. In neoadjuvant and first-line treatment, letrozole demonstrated superior efficacy compared with tamoxifen in randomized Phase III trials. Initial results of Breast InterGroup 1-98, a large ongoing randomized trial investigating primary adjuvant endocrine treatment with either letrozole or tamoxifen, have recently been presented. Patients treated with letrozole demonstrated a 19% improvement in disease-free survival and a significant reduced risk of distant recurrences, holding out the prospect of a survival advantage over tamoxifen treatment with further maturation of the trial. For patients who have already completed 5 years of tamoxifen, extended endocrine therapy with letrozole is a new therapeutic option based on the results of the MA-17 trial. The optimal use of aromatase inhibitors remains an open question, at least until results from randomized trials (BIG 1-98, TEAM) investigating the sequential use of an aromatase inhibitor and tamoxifen in comparison with continuous monotherapy become available. SN - 1744-8328 UR - https://www.unboundmedicine.com/medline/citation/16375638/Letrozole_as_adjuvant_endocrine_therapy_in_postmenopausal_women_with_breast_cancer_ DB - PRIME DP - Unbound Medicine ER -